Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression (Q46200033)

20 December 2017

title

Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression (English)

1 reference

20 December 2017

1 reference

3

Susan L McElroy

1 reference

20 December 2017

Paul E. Keck

4

object named as

Paul E Keck

1 reference

20 December 2017

Mauricio Tohen

7

object named as

Mauricio Tohen

1 reference

20 December 2017

author name string

Eileen Brown

1

1 reference

20 December 2017

David L Dunner

2

1 reference

20 December 2017

David H Adams

5

1 reference

20 December 2017

Elisabeth Degenhardt

6

1 reference

20 December 2017

John P Houston

8

1 reference

20 December 2017

publication date

11 December 2008

1 reference

20 December 2017

The International Journal of Neuropsychopharmacology

published in

1 reference

20 December 2017

volume

12

1 reference

20 December 2017

issue

6

1 reference

20 December 2017

page(s)

773-782

1 reference

20 December 2017

A rating scale for mania: reliability, validity and sensitivity

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

Extending indications for long-term pharmacotherapy: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

Advances in the pharmacologic treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

Psychosocial Disability in the Course of Bipolar I and II Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

7 January 2021

Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

7 January 2021

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

7 January 2021

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

7 January 2021

A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

7 January 2021

Practice guideline for the treatment of patients with bipolar disorder (revision)

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

7 January 2021

The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

7 January 2021

Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

7 January 2021

Characterizing barriers, challenges and unmet needs in the management of bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708009735

7 January 2021

10.1017/S1461145708009735

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

19079815

1 reference

20 December 2017